- The 8 States Most Likely to Legalize Marijuana Next
- Behind Russia's Current Crisis: It's Not the Ruble, It's Putin
- Would you invest in the U.S. Postal Service?
- Why Jim Cramer Says it Could be Too Late to Enter the Stock Market Rally Now
- Apple (AAPL) Stock Declining Today Amid Allegations of Poor Working Conditions in China
A key question is whether Abraxane will be used more than a cheaper, four-drug chemo cocktail.
Contributor Nate Sadeghi works the numbers and says Sarepta is still under-valued.
Improved treatments for pancreatic cancer challenge the relevance of Threshold's TH-302
A longer study blind suggests eteplirsen is really helping muscular dystrophy patients.
Idenix shares are dead money due to FDA safety concerns about Idenix's lead hepatitis C drug.
Believers in Peregrine's lung cancer drug bavituximab state their case.
Nate Sadeghi examines Peregrine's lung cancer drug bavituximab
Nate Sadeghi answers critics who think he's being too hard on Sarepta and its DMD drug eteplirsen.
There are legit reasons to like Sarepta Therapeutics but only if these red flags can be avoided.
The company's pipeline could deliver an upside surprise, plus you get a 4% dividend while you wait.